Episodes

  • Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 

    Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 
    Dec 5 2024
    Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.
    Show More Show Less
    1 hr
  • 5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

    5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
    Nov 26 2024
    Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.
    Show More Show Less
    11 mins
  • Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

    Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
    Nov 19 2024
    Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
    Show More Show Less
    57 mins
  • Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer

    Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer
    Nov 16 2024
    Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
    Show More Show Less
    1 hr and 4 mins
  • Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

    Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
    Nov 1 2024
    Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
    Show More Show Less
    59 mins
  • Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

    Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
    Oct 25 2024
    Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
    Show More Show Less
    46 mins
  • Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors

    Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors
    Oct 18 2024
    Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.
    Show More Show Less
    59 mins
  • Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

    Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
    Sep 25 2024
    Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.
    Show More Show Less
    50 mins